Aprea Therapeutics (APRE) Research & Development (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Research & Development of $1.6 million for Q1 2026, down 35.11% year-over-year from $2.5 million in Q1 2025, and up 59.71% quarter-over-quarter from $1.0 million in Q4 2025.
Aprea Therapeutics (APRE) Research & Development (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Research & Development for 9 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 35.11% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $6.2 million (down 39.77% YoY), while the FY2025 annual figure was $7.0 million, down 24.78% from the prior year.
- Research & Development advanced to $1.6 million in Q1 2026 per APRE's latest filing, from $1.0 million in the prior quarter.
- Across five years, Research & Development topped out at $6.8 million in Q2 2022 and bottomed at $531406.0 in Q4 2022.
- Historically, Research & Development has averaged $2.2 million across 5 years, with a median of $2.0 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 88.09% — and 2023, when it surged 284.96%.
- Aprea Therapeutics' Research & Development stood at $531406.0 in 2022, then soared by 284.96% to $2.0 million in 2023, then increased by 15.32% to $2.4 million in 2024, then slumped by 57.24% to $1.0 million in 2025, then jumped by 59.71% to $1.6 million in 2026.
- Business Quant data shows APRE's Research & Development at $1.6 million in Q1 2026, $1.0 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 2.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.46 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 2.36 Mn |
| Sep 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 531,406.00 |
| Sep 30, 2022 | 1.12 Mn |
| Jun 30, 2022 | 6.81 Mn |
| Mar 31, 2022 | 4.09 Mn |
| Dec 31, 2021 | 4.46 Mn |
| Sep 30, 2021 | 6.02 Mn |